Biology of Human Tumors Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2591-2600

  Blume Jensen, Peter ^a,k   Berman, David M ^b   Rimm, David L ^c   Shipitsin, Michail ^a   Putzi, Mathew ^d   Nifong, Thomas P ^a   Small, Clayton ^a   Choudhury, Sibgat ^a   Capela, Teresa ^a   Coupal, Louis ^e   Ernst, Christina ^a   Hurley, Aeron ^a   Kaprelyants, Alex ^a   Chang, Hua ^a   Giladi, Eldar ^a,j   Nardone, Julie ^a   Dunyak, James ^a   Loda, Massimo ^f   Klein, Eric A ^g   Magi Galluzzi, Cristina ^g   Latour, Mathieu ^h   Epstein, Jonathan I ⁱ   Kantoff, Philip ^f   Saad, Fred ^h   more..

^a Metamark Genetics Inc   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Austin Urology   (United States)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

^j Atreca Inc   (United States)

^k XTuit Pharmaceuticals Lab Central   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOASSAY; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; VALIDATION STUDY; AGED; BIOSYNTHESIS; BLOOD; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEOMICS; RISK ASSESSMENT;

EID: 84941947994     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2603     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Epstein JI. An update of the Gleason grading system. J Urol 2010;183: 433-40.
3. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR, Ca PI. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008;180:1330-4.
4. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65: 1046-55.
5. Sandhu GS, Andriole GL. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr 2012;2012:146-51.
6. NCCN. NCCN clinical practice guidelines in oncology: prostate cancer. Version 3.2012. Available from: http://www.nccn.org/professionals/ physician-gls/-f-guidelines.asp#prostate-detection. Accessed 18 Feb 2014.
7. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
8. Bangma CH, Roobol MJ. Defining and predicting indolent and low risk prostate cancer. Crit Rev Oncol Hematol 2012;83:235-41.
9. Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, et al. Contemporary grading for prostate cancer: implications for patient care. Eur Urol 2013;63:892-901.
10. Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 2013;119:3992-4002.
11. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012;61:1019-24.
12. Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 2006;176:979-84.
13. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, et al. Changes in prostate cancer grade on serial biopsy inmen undergoing active surveillance. J Clin Oncol 2011;29:2795-800.
14. Goodman M, Ward KC, Osunkoya AO, Datta MW, Luthringer D, Young AN, et al. Frequency and determinants of disagreement and error in gleason scores: a population-based study of prostate cancer. Prostate 2012;72: 1389-98.
15. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:869-75.
16. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) < 6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346-52
17. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al.Gleason score and lethal prostate cancer:does 3 + 4 = 4 + 3' J Clin Oncol2009;27:3459-64
18. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428-34.
19. Cuzick J, Berney DM, Fisher G, Mesher D, Moller H, Reid JE, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservativelymanaged needle biopsy cohort. Br J Cancer 2012; 106:1095-9.
20. Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008; 26:3923-9.
21. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-73.
22. Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer 2014; 111:1201-12.
23. Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, et al. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Sci 2014;12:40.
24. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013;111:753-60.
25. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 2012;188:2219-24.
26. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
27. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in nodenegative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
28. Vickers AJ, Elkin EB. Decision curve analysis: a novelmethod for evaluating prediction models. Med Decis Making 2006;26:565-74.
29. Graefen M, Walz J, Chun KH, SchlommT, Haese A, Huland H. Reasonable delay of surgical treatment in men with localized prostate cancer-impact on prognosis? Eur Urol 2005;47:756-60.
30. HolmstromB, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, et al. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 2010;184:1322-7.
31. Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2006;106:576-80.
32. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550-60.
33. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. Abiopsybased 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2014 Nov 29. [Epub ahead of print].
34. Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin 2014; 30:1025-31.